Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Nov 10, 2020 04:05PM
Pre-Open Stock Movers 10/12: (DDS) (DOYU) (TWLO) Higher; (ATXI) (PCG) Lower (more...) Oct 12, 2020 09:29AM
Biogen (BIIB), Alkermes (ALKS) Report FDA Approval of VUMERITY (diroximel fumarate) for Multiple Sclerosis Oct 30, 2019 07:40AM
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis Oct 30, 2019 07:30AM
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis Oct 30, 2019 07:30AM


Oct 30, 2019 07:30AM Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
Jul 30, 2019 07:30AM Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Jul 30, 2019 07:30AM Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Jul 30, 2019 07:30AM Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
May 30, 2019 07:36AM Biogen (BIIB) Announces New Phase 3 Interim Results Support Safety & Efficacy of Diroximel Fumarate in Multiple Sclerosis
May 30, 2019 07:30AM New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
May 30, 2019 07:30AM New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
Feb 25, 2019 07:37AM Alkermes (ALKS) and Biogen (BIIB) Announce FDA Acceptance of Diroximel Fumarate NDA for MS
Feb 25, 2019 07:30AM Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Feb 25, 2019 07:30AM Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Feb 25, 2019 07:30AM Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Dec 17, 2018 07:32AM Alkermes (ALKS) and Biogen (BIIB) Announce Submission of NDA to FDA for Diroximel Fumarate in Multiple Sclerosis
Dec 17, 2018 07:30AM Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Dec 17, 2018 07:30AM Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Dec 17, 2018 07:30AM Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Nov 27, 2017 07:02AM Biogen (BIIB) and Alkermes (ALKS) Announce Pact to Develop and Commercialize ALKS 8700 for Treatment of MS
Nov 27, 2017 07:00AM Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Nov 27, 2017 07:00AM Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Jan 21, 2016 09:28AM Pre-Open Stock Movers 01/21: (ZFGN) (XLNX) (FEYE) Higher; (OGXI) (ALKS) (SLM) Lower (more...)
Apr 8, 2014 09:29AM Pre-Open Stock Movers 4/8: (ALKS) (SHLM) (TWTR) Higher; (JRCC) (GIMO) (SPNC) Lower (more...)